GlaxoSmithKline may soon be selling a pharmacogenomic competitor to Herceptin.

"The results that we've reported have been in studies that have been specific to women with breast cancer [whose] cancer cells are overexpressing [Her2]," a GlaxoSmithKline spokesperson told Pharmacogenomics Reporter this week. "It's like Herceptin in that way."

Glaxo halted enrollment for a phase 3 trial involving its breast-cancer drug Tykerb when the study reached its primary endpoint — time to disease progression — early in women who had failed Herceptin therapy.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.